Sutro Biopharma (NASDAQ:STRO) Upgraded by Wall Street Zen to Hold Rating

Sutro Biopharma (NASDAQ:STRO) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also commented on the company. Wedbush reiterated a “neutral” rating and set a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Citigroup upgraded Sutro Biopharma to an “outperform” rating in a research report on Tuesday, January 20th. HC Wainwright upgraded Sutro Biopharma from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $10.00 to $28.00 in a research note on Tuesday. Deutsche Bank Aktiengesellschaft raised their target price on Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Citizens Jmp raised shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price target for the company in a report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.29.

Sutro Biopharma Stock Down 1.9%

Shares of NASDAQ:STRO opened at $24.43 on Friday. The company has a market cap of $207.90 million, a PE ratio of -0.94 and a beta of 1.47. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $26.54. The firm has a 50-day simple moving average of $19.06 and a 200 day simple moving average of $12.94.

Institutional Trading of Sutro Biopharma

Institutional investors have recently made changes to their positions in the stock. State of Tennessee Department of Treasury bought a new position in shares of Sutro Biopharma in the fourth quarter valued at approximately $86,000. Jane Street Group LLC bought a new stake in Sutro Biopharma during the fourth quarter worth approximately $265,000. Bridgeway Capital Management LLC lifted its position in Sutro Biopharma by 232.6% in the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after purchasing an additional 30,000 shares during the period. ADAR1 Capital Management LLC bought a new position in Sutro Biopharma during the 4th quarter valued at $776,000. Finally, Spruce Street Capital LP bought a new position in Sutro Biopharma during the 4th quarter valued at $875,000. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma News Roundup

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55, signaling strong upside from current levels; that lift to a much higher PT supports bullish investor sentiment. Deutsche Bank Raises Price Target to $55
• Positive Sentiment: Wells Fargo upgraded Sutro to “Overweight,” an endorsement that can attract institutional buying. Wells Fargo Upgrades Sutro Biopharma to Overweight
• Positive Sentiment: Truist moved the stock to “strong-buy” (reported via Zacks), another supportive vote of confidence from the sell side. Truist Upgrades to Strong-Buy (Zacks)
• Neutral Sentiment: HC Wainwright published commentary on Sutro’s FY2030 outlook — the note offers long‑range modeling context but is not a straightforward buy/sell trigger by itself. HC Wainwright Comments on Sutro FY2030 Earnings
• Negative Sentiment: HC Wainwright sharply cut near‑term and multi‑year EPS forecasts (Q1–Q4 FY2026 and FY2026–FY2029), moving projected losses much deeper while keeping a Buy rating and a $28 target. Those sizable downward revisions increase short‑term downside risk and help explain selling pressure despite upgrades. HC Wainwright Lowers Multiple EPS Estimates (MarketBeat)

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.